financetom
Business
financetom
/
Business
/
Apogee Enterprises Fiscal Q3 Adjusted Earnings Decline, Sales Rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Apogee Enterprises Fiscal Q3 Adjusted Earnings Decline, Sales Rise
Jan 7, 2025 4:13 AM

06:56 AM EST, 01/07/2025 (MT Newswires) -- Apogee Enterprises ( APOG ) reported fiscal Q3 adjusted earnings Tuesday of $1.19 per diluted share, down from $1.23 a year earlier.

Four analysts polled by FactSet expected $1.10.

Net sales for the fiscal quarter ended Nov. 30 were $341.3 million, up from $339.7 million a year earlier.

Four analysts polled by FactSet expected $332.3 million.

For fiscal 2025, the engineering and design firm said it now expects adjusted EPS at the bottom of its guidance range of $4.90 to $5.20 on net sales decline of about 5%. Four analysts polled by FactSet expect adjusted EPS of $5.07 on sales of $1.35 billion.

Shares of the company fell over 1% in recent premarket activity Tuesday.

Price: 69.99, Change: -1.14, Percent Change: -1.60

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment
Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment
Apr 16, 2024
08:57 AM EDT, 04/16/2024 (MT Newswires) -- Cybin ( CYBN ) said Tuesday the United States Patent and Trademark Office has awarded US patent 11,958,807 for its CYB003 program in treating major depressive disorder. The patent, offering exclusivity until at least 2041, includes pharmaceutical compositions under Cybin's ( CYBN ) proprietary deuterated psilocybin analog program, CYB003. Cybin ( CYBN )...
BioRestorative Therapies Says US FDA Clears Amended Protocol for Phase 2 Cell Therapy Trial
BioRestorative Therapies Says US FDA Clears Amended Protocol for Phase 2 Cell Therapy Trial
Apr 16, 2024
08:56 AM EDT, 04/16/2024 (MT Newswires) -- BioRestorative Therapies ( BRTX ) said Tuesday that the US Food and Drug Administration has cleared an amendment to the protocol of the current phase 2 trial of its cell therapy candidate, BRTX-100, to treat chronic lumbar disc disease. The amendment replaces saline injections with sham injections in the control group, the company...
K92 Mining Q1 Production at Kainantu Mine Rises 28% Despite Temporary Suspension of Operations
K92 Mining Q1 Production at Kainantu Mine Rises 28% Despite Temporary Suspension of Operations
Apr 16, 2024
08:56 AM EDT, 04/16/2024 (MT Newswires) -- K92 Mining ( KNTNF ) on Tuesday said first-quarter production from its Kainantu mine in Papua New Guinea rose 28%, even as production was suspended for the last three weeks of the period after the death of an employee on the site. The company said it produced 27,462 gold-equivalent ounces of gold and...
Ballard Up 0.35% In US Premarket As Announces Orders for 70 Hydrogen Fuel Cell Engines by UK Bus Company
Ballard Up 0.35% In US Premarket As Announces Orders for 70 Hydrogen Fuel Cell Engines by UK Bus Company
Apr 16, 2024
08:56 AM EDT, 04/16/2024 (MT Newswires) -- Ballard Power Systems ( BLDP ) was at last look up 0.35% in US premarket on Tuesday after announcing multiple purchase orders totaling 70 FCmove-HD hydrogen fuel cell engines from Wrightbus a UK-based bus manufacturer deploying hydrogen-powered buses in the UK and Europe. Ballard expects to deliver the fuel cell engines in 2024,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved